SK2902003A3 - Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
SK2902003A3
SK2902003A3 SK290-2003A SK2902003A SK2902003A3 SK 2902003 A3 SK2902003 A3 SK 2902003A3 SK 2902003 A SK2902003 A SK 2902003A SK 2902003 A3 SK2902003 A3 SK 2902003A3
Authority
SK
Slovakia
Prior art keywords
fluoroanilino
chloro
methyl
phenylacetic acid
pharmaceutically acceptable
Prior art date
Application number
SK290-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Simon David Bateman
Alberto Gimona
Jurij Holinej
Jasper Huels
Sumedha Jayawardene
Argeris Jerry Karabelas
Maha Y Khaled
Anees Abdulquadar Karnachi
Lochlainn Eimear Mairin Nic
Richard Macerata
Victor Sloan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK2902003A3 publication Critical patent/SK2902003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK290-2003A 2000-09-11 2001-09-10 Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof SK2902003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US23226100P 2000-09-14 2000-09-14
PCT/EP2001/010448 WO2002020090A2 (fr) 2000-09-11 2001-09-10 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
SK2902003A3 true SK2902003A3 (en) 2003-10-07

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
SK290-2003A SK2902003A3 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof

Country Status (28)

Country Link
US (2) US20020061932A1 (fr)
EP (1) EP1331972B1 (fr)
JP (2) JP2004527458A (fr)
KR (1) KR20030036730A (fr)
CN (1) CN100490797C (fr)
AR (1) AR030630A1 (fr)
AT (1) ATE366128T1 (fr)
AU (2) AU1390002A (fr)
BR (1) BR0113809A (fr)
CA (1) CA2416771C (fr)
CY (1) CY1107729T1 (fr)
CZ (1) CZ2003673A3 (fr)
DE (1) DE60129238T2 (fr)
DK (1) DK1331972T3 (fr)
ES (1) ES2290181T3 (fr)
HU (1) HUP0301128A3 (fr)
IL (2) IL154238A0 (fr)
MX (1) MXPA03002105A (fr)
MY (1) MY126117A (fr)
NO (1) NO20031095L (fr)
NZ (1) NZ524785A (fr)
PE (1) PE20020351A1 (fr)
PL (1) PL359721A1 (fr)
PT (1) PT1331972E (fr)
RU (1) RU2316324C2 (fr)
SI (1) SI1331972T1 (fr)
SK (1) SK2902003A3 (fr)
WO (1) WO2002020090A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
PE20040288A1 (es) * 2002-03-07 2004-06-24 Novartis Ag Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
EP1539134A4 (fr) 2002-06-11 2007-04-11 Nitromed Inc Inhibiteurs selectifs de cyclooxigenase-2 nitroses et/ou nitrosyles, compositions et methodes d'utilisation
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
EP2043613A1 (fr) * 2006-07-14 2009-04-08 Fmc Corporation Forme solide
WO2008086537A2 (fr) * 2007-01-11 2008-07-17 Analog Devices, Inc. Métallisation à base d'aluminium de tranches semi-conductrices
CN102197144A (zh) * 2008-08-22 2011-09-21 诺瓦提斯公司 Cox-2抑制剂用于治疗不携带与肝脏毒性相关的hla等位基因的患者中cox-2依赖性疾病的用途
US8227451B2 (en) 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 磷虾油的制备方法
CA3076907A1 (fr) 2017-09-26 2019-04-04 Tesaro, Inc. Formulations de niraparib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701449B1 (fr) * 1993-06-08 2003-08-06 Novartis AG Procede de preparation d'une forme galenique orale solide contenant du diclofenac
KR100373622B1 (ko) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
BR0113809A (pt) 2003-07-29
KR20030036730A (ko) 2003-05-09
DE60129238T2 (de) 2008-03-06
AU2002213900C1 (en) 2006-07-27
US20040186179A1 (en) 2004-09-23
NO20031095D0 (no) 2003-03-10
IL154238A0 (en) 2003-09-17
US20020061932A1 (en) 2002-05-23
CY1107729T1 (el) 2013-04-18
CN100490797C (zh) 2009-05-27
PL359721A1 (en) 2004-09-06
NZ524785A (en) 2005-10-28
AU1390002A (en) 2002-03-22
DK1331972T3 (da) 2007-11-05
MY126117A (en) 2006-09-29
ATE366128T1 (de) 2007-07-15
ES2290181T3 (es) 2008-02-16
HUP0301128A3 (en) 2005-04-28
CN1455691A (zh) 2003-11-12
PE20020351A1 (es) 2002-06-14
AU2002213900B2 (en) 2006-02-16
WO2002020090A3 (fr) 2003-05-30
EP1331972B1 (fr) 2007-07-04
WO2002020090A2 (fr) 2002-03-14
JP2004527458A (ja) 2004-09-09
CA2416771C (fr) 2010-11-02
WO2002020090A9 (fr) 2003-10-30
CZ2003673A3 (cs) 2003-06-18
IL154238A (en) 2008-11-26
EP1331972A2 (fr) 2003-08-06
PT1331972E (pt) 2007-10-16
RU2316324C2 (ru) 2008-02-10
HUP0301128A2 (hu) 2003-10-28
SI1331972T1 (sl) 2007-12-31
NO20031095L (no) 2003-03-10
MXPA03002105A (es) 2003-06-19
CA2416771A1 (fr) 2002-03-14
JP2011144194A (ja) 2011-07-28
DE60129238D1 (de) 2007-08-16
AR030630A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
US20070231382A1 (en) Pharmaceutical composition
JP2011144194A (ja) 医薬組成物
AU2002331094A1 (en) Pharmaceutical composition comprising lumiracoxib
AU2002213900A1 (en) Pharmaceutical compositions
JP2004527458A5 (fr)
CA3001288C (fr) Formulation a liberation modifiee de naproxene sodique
US20090149543A1 (en) Solid pharmaceutical compositions comprising lumiracoxib
ZA200300555B (en) Pharmaceutical compositions.
Rameshgiri Development and Evaluation of Controlled Release Matrix Tablets of Diltiazem Hydrochloride Using Natural Polymers

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure